10-Q · May 15, 2026
Citius Pharmaceutical's Q2 2026 10-Q reveals a notable increase in product revenue with the commercial launch of LYMPHIR, generating $1.67 million in revenue for the quarter. However, the company reported a substantial…
Earnings analysis · 10-Q
CTXR earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The latest quarter showed $2.0 million of revenue, down 50.0% sequentially from $4.0 million, while diluted EPS deteriorated to -$0.95 from -$0.38. Gross margin was resilient at 80.3%, but operating margin was deeply…
Read full summary
The latest quarter showed $2.0 million of revenue, down 50.0% sequentially from $4.0 million, while diluted EPS deteriorated to -$0.95 from -$0.38. Gross margin was resilient at 80.3%, but operating margin was deeply negative at -1,931.0%. The filing adds material financing risks at Citius Oncology, including a 12.75% interest-rate floor, a $1,062,500 maturity payment, and milestone-dependent access to Tranches 2 and 3.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Reported figures
- Earnings per share
- $-0.95
- Segment
- LYMPHIR: revenue contribution is not separately quantified in the provided filing text
What stood out
-
Gross margin remains above 80%
Gross margin remained strong at 80.3% in the latest quarter, broadly stable versus 80.0% in the prior quarter and 80.3% in the comparable available period.
-
LYMPHIR remains the revenue focus
The company reported $2.0 million of revenue in the latest quarter, with LYMPHIR identified in the filing data as the principal product revenue category.
-
Controls assessed as effective
Disclosure controls and procedures were concluded effective as of June 30, 2026, and management reported no material changes to internal control over financial reporting during the quarter.
What to watch
-
High-cost debt and balloon payment
Citius Oncology’s loan carries a floating interest rate with a 12.75% annual floor, includes interest-only payments before amortization, and requires a $1,062,500 final payment at maturity, increasing refinancing and liquidity risk.
-
Milestone-dependent funding
Access to Tranche 2 and Tranche 3 is conditional on specified net revenue and liquidity milestones; failure to meet those milestones would eliminate access to additional committed capital under the loan agreement.
-
Potential equity dilution
Lenders may convert up to $4.0 million of principal at $1.08 per share and hold warrants equal to 10% of funded loans exercisable at $0.90 per share, creating potential dilution and market-price pressure.
Management's outlook
The provided 10-Q extract contains no quantitative revenue or EPS outlook. Prior commentary referenced ongoing LYMPHIR-driven revenue growth, but this filing excerpt does not provide updated numeric guidance.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.